Viatris Inc. (VTRS:NASDAQ) closed at $18.15 on October 15, 2026, up 4.07% on the day. The stock trades 1.5% below its 52-week high of $18.43 and 83.0% above its 52-week low of $9.92. Over the past year, it gained 74.7%. Viatris Inc. is part of the Miscellaneous sector.
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -0.57% | +4.74% | +0.87% | +17.28% | +74.75% |
In 252 trading sessions since October 14, 2025, VTRS closed higher on 136 days (54%). Its best day was November 11, 2025 (+10.13%) and its worst was August 6, 2026 (-7.71%). The stock moved 10% or more in a single session 1 time.
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio and nascent biosimilar portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Find more stocks like VTRS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.